辰欣药业股份有限公司 2023 年年度股东大会 会议资料 二 0 二四年五月 辰欣药业股份有限公司 2023 年年度股东大会会议资料 2023 年年度股东大会会议议程 现场会议时间：2024 年 5 月 21 日下午 13:30 投票方式：现场投票与网络投票相结合 网络投票时间：辰欣药业股份有限公司（以下简称 "公司"或"辰欣药业"）采 用上海证券交易所股东大会网络投票系统，通过交易系统投票平台的投票时间为股东 大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联网投 票平台的投票时间为股东大会召开当日的 9:15-15:00。 2、审议《关于公司 2023 年度董事会工作报告的议案》 3、审议《关于公司 2023 年度独立董事述职报告的议案》 签到时间：2024 年 5 月 21 日 下午：13:00-13:20 现场会议地点：山东省济宁市高新区同济路 16 号辰欣药业股份有限公司一园区办 公楼六楼会议室 会议主持人：董事长杜振新先生 一、会议议程 1、宣布会议开始 2、主持人宣布会议开始并向股东大会介绍参会股东和股东代表及列席人员情况； 3、董事会秘书宣 ...

证券代码：603367 证券简称：辰欣药业 公告编号：2024-038 辰欣药业股份有限公司 关于 2023 年度暨 2024 年第一季度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 问题 1：请问： （1）公司特医食品产销情况如何，何时才能销售百亿元。 辰欣药业股份有限公司（以下简称"辰欣药业"或"公司"）于 2024 年 5 月 9 日（星期四）上午 10:00-11:00 在上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com）, 以网络文字互动方式召开了公司 2023 年度暨 2024 年第一季度业绩说明会。就投资者普遍关心和关注的问题进行了互动交流 沟通。现将召开情况公告如下： 一、业绩说明会的召开情况 公司于 2024 年 4 月 23 日在上海证券交易所网站（www.sse.com.cn）和信息 披露指定媒体披露了《辰欣药业股份有限公司关于召开 2023 年度暨 2024 年第一 季度业绩说明会的公告》（公告编号：2024-034）。 2024 年 ...

证券代码：603367 证券简称：辰欣药业 公告编号：2024-039 辰欣药业股份有限公司 关于持股 5%以上股东集中竞价减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 大股东持股的基本情况 截至本次减持计划披露之日，辰欣药业股份有限公司（以下简称"公司"或 "辰欣药业"）持股 5%以上股东北海辰昕创业投资有限公司（以下简称"北海辰 昕"）持有辰欣药业无限售流通股份 46,782,021 股，占辰欣药业总股本的 10.33%。 上述股份来源均为公司首次公开发行前股份，且已与 2018 年 10 月 11 日全部解 除限售并上市流通。 集中竞价减持计划的主要内容 自本公告披露之日起满 15 个交易日后的 3 个月内，北海辰昕拟通过集中竞 价交易方式合计减持数量不超过 4,527,751 股，不超过公司总股本的 1%。在任 意连续 90 日内，减持股份的总数不超过公司股份总数的 1%。在上述减持计划实 施期间，公司发生派发红利、送红股、转增股本、增发新股或配股等股本变动股 本除权、除息 ...

辰欣药业股份有限公司 证券代码：603367 证券简称：辰欣药业 公告编号：2024-037 关于实际控制人、董事长兼总经理增持股份 计划实施完毕暨增持结果的公告 本次增持计划实施结果：截至本公告披露日，杜振新先生已通过上海证券交 易所交易系统以集中竞价交易方式合计增持公司股份 1,875,100 股，占公司总股 本的 0.41%，合计增持金额为人民币 21,891,097.28 元，增持金额超过本次增持 计划的区间下限，本次增持计划已实施完毕。 公司于 2024 年 5 月 6 日收到杜振新先生《关于增持公司股份计划实施完毕 暨增持结果的告知函》，现将相关情况公告如下： 一、增持主体的基本情况 1、增持主体：辰欣药业实际控制人、董事长兼总经理杜振新先生 2、增持主体本次增持前持股情况： 本次增持前，杜振新先生及一致行动人辰欣科技集团有限公司、北海辰昕创 业投资有限公司、卢秀莲女士合计持有辰欣药业 167,437,100 股份，占公司总股 本的比例为 36.98%。其中，杜振新先生直接持有辰欣药业 1,763,900 股股份， 1 / 3 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或 ...

关于辰欣药业股份有限公司实际控制人、董事长 兼总经理增持公司股份的专项核查意见 北京市盈科（济南）律师事务所 济南市历下区经十路11111号济南华润中心39层 郎编：250014 电话： (86)0531-55698000 传真： (86) 0531-5569811 北京市盈科（济南）律师事务所 7 北京市盈科 (济南) 律师事务所 关于辰欣药业股份有限公司实际控制人、董事长 兼总经理增持公司股份的专项核查意见 【2024】盈济南非诉字第 JN 号 致: 辰欣药业股份有限公司 北京市盈科(济南)律师事务所(以下简称"本所")接受辰欣药业股份有 限公司（以下简称"公司"、"辰欣药业"）委托，根据《中华人民共和国公司 法》（以下简称"《公司法》"）《中华人民共和国证券法》（以下简称"《证 券法》"）《上海证券交易所股票上市规则》（以下简称"《上市规则》"） 《上市公司收购管理办法》（以下简称"《收购管理办法》"）《上海证券交易 所上市公司自律监管指引第 8 号 -- 股份变动管理》(以下简称"《8 号指 引》"） 等有关法律、行政法规、部门规章、规范性文件以及《辰欣药业股份 有限公司章程》的有关规定，就辰欣药业实 ...

Investment Rating - The investment rating for the company is "Buy-A" with a target price of 21.42 CNY for the next 6 months [1][12]. Core Insights - The company is expected to benefit from the recovery in demand for large-volume infusion products and continuous expansion of new products, leading to steady growth [11]. - The overall gross margin for the company improved to 58.79% in 2023, an increase of 2.80 percentage points year-on-year [11]. - The company’s revenue and net profit for Q1 2024 were 1.149 billion CNY and 163 million CNY, respectively, representing year-on-year growth of 1.28% and 4.50% [11]. Financial Performance - The company is projected to achieve revenues of 4.956 billion CNY, 5.437 billion CNY, and 5.868 billion CNY for 2024, 2025, and 2026, respectively, with year-on-year growth rates of 11.06%, 9.69%, and 7.94% [25]. - The expected net profits for 2024, 2025, and 2026 are 573 million CNY, 623 million CNY, and 674 million CNY, with growth rates of 9.8%, 8.7%, and 8.3% [12][25]. - The earnings per share (EPS) for 2024 is estimated to be 1.26 CNY, with a price-to-earnings (PE) ratio of 17 times [12][32]. Market Position and Industry Outlook - The large-volume infusion industry has seen an improvement in supply-demand dynamics, which is expected to enhance the company's profitability [5][11]. - The company has successfully bid for several new products in the eighth batch of centralized procurement, which is anticipated to drive rapid sales growth [11]. - The overall market for medical institutions is recovering, with the total number of medical visits in China increasing from 460 million in January 2023 to 602 million in August 2023 [11].

Financial Performance - The company's operating revenue for 2023 reached ¥4,462,348,636.07, representing a year-on-year increase of 9.75% compared to ¥4,066,088,448.57 in 2022 [23]. - Net profit attributable to shareholders was ¥521,338,330.89, a significant increase of 48.97% from ¥349,958,583.46 in the previous year [23]. - The basic earnings per share for 2023 was ¥1.15, up 49.35% from ¥0.77 in 2022 [25]. - The weighted average return on equity increased to 9.49%, up 2.73 percentage points from 6.76% in 2022 [25]. - The net cash flow from operating activities was ¥451,240,761.60, reflecting a 74.67% increase from ¥258,345,605.17 in 2022 [23]. - Total assets at the end of 2023 amounted to ¥7,337,838,152.94, a 7.67% increase from ¥6,815,073,080.14 at the end of 2022 [24]. - The company's net assets attributable to shareholders increased by 7.41% to ¥5,727,355,807.20 from ¥5,332,181,340.75 in 2022 [24]. - The total profit for 2023 was 596 million RMB, an increase of 62.72% compared to the previous year [33]. - The net profit attributable to the parent company was 521 million RMB, reflecting a growth of 48.97% year-on-year [33]. - The net profit excluding non-recurring gains and losses was 451 million RMB, up 36.21% from the previous year [33]. Dividend Distribution - The company plans to distribute a cash dividend of 4.36 RMB per 10 shares, totaling approximately 197.41 million RMB based on the distribution plan [6]. - The company has a total of 452,764,629 shares eligible for dividend distribution, excluding 10,500 shares pending repurchase [6]. - The total cash dividend amount distributed was RMB 197,405,378.24, which represents 37.87% of the net profit attributable to ordinary shareholders in the consolidated financial statements [181]. - The company maintains a continuous and stable profit distribution policy, considering both investor returns and long-term development needs [175]. - The profit distribution plan was approved by the shareholders' meeting, ensuring the protection of minority shareholders' rights [175]. Research and Development - The company has increased its R&D investment, focusing on quality control and clinical value optimization [36]. - R&D investment accounts for over 8% of the company's revenue, supporting sustainable development and transformation [57]. - The company has over 100 ongoing R&D projects focused on complex injection agents, controlled-release oral solid preparations, and new drugs for major clinical needs [90]. - The company is committed to research and development of innovative therapies for chronic diseases, including hepatitis and cardiovascular conditions [84]. - The company is actively pursuing new drug development in areas such as anti-infection and diabetes management [98]. Market Strategy and Expansion - The company plans to continue expanding its market presence and investing in new product development to sustain growth in the coming years [23]. - The company is actively expanding its market presence in OTC drugs, special medical foods, and traditional Chinese medicine products [34]. - The company is focusing on expanding its market presence through strategic acquisitions and partnerships in the pharmaceutical sector [86]. - The company is enhancing its CRM system and budget management to strengthen market and business management functions [34]. - The company is adapting its business strategies in response to regulatory changes in the pharmaceutical industry, aiming to accelerate product approvals and market entry [51]. Compliance and Governance - The company has established a comprehensive internal control governance structure to maintain independence from its actual controllers [134]. - The company adheres to strict information disclosure practices, ensuring transparency and equal access to information for all shareholders [134]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with governance regulations [133]. - The company has established specialized committees within the board, including an audit committee, nomination committee, compensation and assessment committee, and strategic committee [155]. - The company emphasizes maintaining independence and operational capability during the spin-off process [151]. Environmental Responsibility - The company invested 20.34 million yuan in environmental protection during the reporting period [191]. - The company has installed activated carbon treatment equipment to ensure that emissions meet standards, with regular third-party disposal of hazardous waste [194]. - The company has undergone multiple environmental impact assessments for various projects, including a production capacity of 30 million soft-pack intravenous solutions annually [195]. - The company has not experienced any environmental incidents during the reporting period [199]. - The actual concentration of COD was 41.75 mg/L, significantly below the limit of 500 mg/L [200]. Risks and Challenges - The company faces risks from intensified market competition, with potential threats from competitors launching more effective or cost-effective products [127]. - Raw material price fluctuations can adversely affect production costs and profitability, prompting the company to implement a procurement strategy to manage these risks [129]. - The pharmaceutical manufacturing industry is significantly impacted by policy changes, including revisions to drug management laws and adjustments to medical insurance catalogs [127]. - Environmental regulations pose risks to production operations, necessitating the establishment of an environmental management department to enhance operational capabilities [129]. - In 2023, the pharmaceutical industry in China is expected to face significant challenges due to rising costs in research, labor, and production, alongside intensified competition and regulatory scrutiny [41].

证券代码：603367 证券简称：辰欣药业 公告编号：2024-030 辰欣药业股份有限公司 关于 2023 年年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 本次利润分配方案尚需提交公司股东大会审议。 重要内容提示： 每 10 股派发现金红利 4.36 元（含税），不以公积金转增股本，不送红 股。 本次利润分配以实施权益分派股权登记日登记的总股本扣除公司 1 名 股权激励对象辞职待回购注销的股份 10,500 股的余额为基数，具体日期将在权 益分派实施公告中明确。 在实施权益分派的股权登记日前公司总股本发生变动的，公司拟维持 每股分配股利不变，相应调整分配总额。并将另行公告具体调整情况。 本次利润分配方案已经公司第五届董事会第三次会议审议通过，尚需 提交公司股东大会审议。 一、利润分配方案内容 根据大信会计师事务所（特殊普通合伙）出具的《辰欣药业股份有限公司审 计报告》，公司 2023 年度实现归属于母公司的净利润 521,338,330.89 元，减去 应付普通股股利 151,679,668. ...

辰欣药业股份有限公司 募集资金存放与实际使用情况 审核报告 大信专审字[2024]第 3-00118 号 大信会计师事务所（特殊普通合伙） WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. 大信会计师事务所 北京市海淀区知春路 1 号 学院国际大厦 22 层 2206 邮编 100083 WUYIGE Certified Public Accountants.LLP Room 2206 22/F, Xueyuan International Tower No.1 Zhichun Road, Haidian Dist. Beijing, China, 100083 电话 Telephone：+86（10）82330558 传真 Fax： +86（10）82327668 网址 Internet： www.daxincpa.com.cn 募集资金存放与实际使用情况审核报告 大信专审字[2024]第 3-00118 号 辰欣药业股份有限公司全体股东： 我们接受委托，对后附的辰欣药业股份有限公司（以下简称"贵公司"）《2023年度募 集资金存放与实际使用情况的专项报告》（以下简称"募集资 ...

证券代码：603367 证券简称：辰欣药业 公告编号：2024-032 辰欣药业股份有限公司关于 2023 年度 日常关联交易确认及 2024 年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 辰欣药业股份有限公司（以下简称"公司"或"辰欣药业"）的日常关 联交易均属公司及下属子公司日常生产经营中的必要的业务，以市场公允价格为 定价标准，交易遵循公平、公正的市场原则，不会影响公司的独立性，公司的主 营业务不会因本次日常关联交易而对关联人形成依赖。 ●本次日常关联交易事项为董事会决策权限，无需提交股东大会审议。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 2024 年 4 月 22 日，公司召开第五届董事会第三次会议和第五届监事会第三 次会议，会议分别审议通过了《关于公司 2023 年度日常关联交易确认及 2024 年度日常关联交易预计的议案》，关联董事杜振新、郝留山、卢秀莲、续新兵、 黄保战回避了表决。本次关联交易事项为董事会决策权限，无需提交股东大会审 议。 公司 ...